Influence of borderline cefepime MIC on the outcome of cefepime-susceptible Pseudomonas aeruginosa bacteremia treated with a maximal cefepime dose: a hospital-based retrospective study

摘要

Background We assessed the influence of current cefepime minimal inhibitory concentration (MIC) breakpoints and the maximal cefepime dose on treatment outcomes in patients with bacteremia caused by cefepime-susceptible Pseudomonas aeruginosa . Methods Adult patients hospitalized between July 2010 and June 2014 with a positive blood culture for cefepime-susceptible P. aeruginosa and receipt of cefepime as the primary therapy throughout the course were reviewed. Cefepime Etest? MICs and clinical outcomes for P. aeruginosa bacteremia were reviewed to identify the MIC breakpoint influencing treatment outcomes. Results Of the 90 patients enrolled, 49 (54.4%) were male (mean age?=?66.8?years). The mean Acute Physiology and Chronic Health Evaluation II score was 22.01. Sixty patients (66.7%) received a maximal cefepime dose, and the 30-day crude mortality rate was 36.7%. MIC₉₀ of cefepime for P. aeruginosa was 8?mg/L. The cumulative survival rate at 30?days revealed that a lower cefepime MIC ( P. aeruginosa was associated with a higher survival rate than a higher MIC (≥4?mg/L) (72.6% vs. 23.5%, p P. aeruginosa bacteremia at a MIC of ≥4?mg/L. Conclusions A cefepime MIC of 4?mg/L may predict an unfavorable outcome among patients with serious infections caused by P. aeruginosa , even the MICs still within the CLSI susceptibility breakpoint.